


30 January 2017

DIAsource Outperforms Expectations for CY2016


- **DIAsource achieve best ever quarter / yearly revenues**
- **Sales performance for Vitamin D products show 142% growth over December quarter 2015**
- **Gross Margins over 50% in 2016 up from 47% in 2015**

Anteo Diagnostics Ltd (**ASX:ADO**) is pleased to report that DIAsource Immunoassays SA, the Belgian subsidiary acquired last year, has completed its first year as part of Anteo with record results.

Sales for the December quarter were €4.855m (AUD 6.87m), a 37% increase over the December quarter in 2015. Sales for the calendar year were €16.347m (AUD 23.16m). This represents 15.5% growth over the previous year and was in excess of acquisition expectation.




Growth was strongest in the Vitamin D line of products. The December quarter was 142% up on the previous corresponding period and the Vitamin D product range achieved 38% growth over the previous year. A key factor in this growth was the 77% growth realised by ELISA Vitamin D products over the previous year.



The Supply Chain continuous improvement program has further progressed and contributed to additional improvements in Gross Margins at DIAsource. Gross Margins have risen to over 50% from 47% in the previous year.

EBITDA for the year was €3.5m (AUD 5m) or 21.4% of revenues. This is up from 17.6% of revenues in 2015 and again ahead of acquisition expectation.



These results are unaudited and additional detail will be provided in the Appendix 4C

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com